Brain Wealthy
    What's Hot

    Bridging the Gender Gap: Inspiring Words from the Women Making Waves on Starship | Annie Handrick | | Starship Technologies | March 2023

    March 8, 2023

    AI apps like ChatGPT may finally kill the cover letter

    March 8, 2023

    Snow Crash author Neal Stephenson on the metaverse, making movies, climate fears

    March 6, 2023
    Facebook Twitter Instagram
    Facebook Twitter Instagram
    Brain Wealthy
    • Home
    • Anxiety

      FSU psychologist receives $3.7 million grant to combat anxiety in seniors with Alzheimer’s and cognitive impairment

      February 2, 2023

      How anxiety came to dominate the big business of medical marijuana cards in Pa.

      February 2, 2023

      How to Reduce Anxiety in Stressful Situations

      February 2, 2023

      The cat in boots The last wish taught me about anxiety

      February 2, 2023

      Inseparable cat trio with ‘separation anxiety brothers’ find new home

      February 2, 2023
    • Emotion

      Leigh-Anne Pinnock shares emotional post about embarking on her solo career

      February 2, 2023

      Ontario paramedic emotional during last radio call

      February 2, 2023

      A Pianist Faces Death and Recorded Music of Unspeakable Emotions

      February 2, 2023

      Return of home post linking Gichaara to ancestors is emotional for north coast nation

      February 2, 2023

      Mother of two sues New York school district for ‘mental distress’ caused by mask enforcement

      February 2, 2023
    • Neurology

      Gardasil Injection Lawsuit Claims HPV Vaccine Caused Neurological and Autonomic Dysfunction

      February 2, 2023

      REGENXBIO’s Duchenne Therapy RGX-202 Clinical Trial Begins Patient Recruitment

      February 2, 2023

      Aducanumab for the treatment of Alzheimer’s disease

      February 2, 2023

      Potential for Effective Comparative Studies and Treatment Approval in Epilepsy Care: Anup Patel, MD

      February 2, 2023

      Head injury does not predict memory impairment in NFL retirees, UT Southwestern study shows: Newsroom

      February 2, 2023
    • Sleep

      Review: Never Sleep Again: The Elm Street Legacy – Blu-ray

      February 2, 2023

      Get a better night’s sleep with better pillows from The Pillow Bar in Dallas

      February 2, 2023

      Is it okay to sleep with a necklace on?

      February 2, 2023

      Does tart cherry juice improve sleep?

      February 2, 2023

      Social Jet Lag, Sleep Chronotypes, and Why We Gotta Close Our Eyes and Embrace It

      February 2, 2023
    • Brain Research

      spark!Talk – video available online

      February 2, 2023

      Studies have found that obesity-related neurodegeneration mimics Alzheimer’s disease.newsroom

      February 2, 2023

      The Brain Observatory: New Museum to Participate in Museum Month

      February 1, 2023

      who wants to live forever

      February 1, 2023

      UK company makes surprise forays

      February 1, 2023
    • Brain Wealth
      1. Mental Health
      2. View All

      Research project applies a global lens to student mental health

      February 2, 2023

      DC Metro shooting suspect undergoes mental health evaluation after rampage

      February 2, 2023

      Gov. Ho-Chol unveils details of $1 billion plan to overhaul New York State’s mental health care continuum

      February 2, 2023

      Boston, we have a problem: data on mental health and practice come in

      February 2, 2023

      Research project applies a global lens to student mental health

      February 2, 2023

      DC Metro shooting suspect undergoes mental health evaluation after rampage

      February 2, 2023

      Gov. Ho-Chol unveils details of $1 billion plan to overhaul New York State’s mental health care continuum

      February 2, 2023

      Boston, we have a problem: data on mental health and practice come in

      February 2, 2023
    Brain Wealthy
    Home»Anxiety»Biomind Labs Announces Completion of First Sublingual Psychedelic Formulation of Drug Candidate BMND08 for Depression and Anxiety in Alzheimer’s Disease
    Anxiety

    Biomind Labs Announces Completion of First Sublingual Psychedelic Formulation of Drug Candidate BMND08 for Depression and Anxiety in Alzheimer’s Disease

    brainwealthy_vws1exBy brainwealthy_vws1exDecember 28, 2022No Comments6 Mins Read
    Facebook Twitter LinkedIn Telegram Pinterest Tumblr Reddit WhatsApp Email
    Share
    Facebook Twitter LinkedIn Pinterest Email


    Toronto – (business wire)– Biomind Labs Inc. (“biomind lab” or “company) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) develops next-generation medicines to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the efficacy of psychedelic molecules is a leading biotechnology company focused on is pleased to announce the successful development of a new sublingual formulation for use in a Phase II trial of 5-Metoxi-N,N-dimethyltryptamine (see5-MeO-DMT‘)-based BMND08 candidates have potential for the treatment of depression and anxiety in Alzheimer’s disease.

    “A new milestone has been reached that strengthens our vertical integration strategy. We have completed production of the first batch of new drug candidates that may enable us to pursue a new line of development to reduce depression and anxiety conditions in patients with Alzheimer’s disease. We are very excited. Over the past few decades, science has proven that life expectancy can be increased, but this perception may not be as good as hoped.? Current lifestyles due to Covid-19, The routine, long-lasting neurological consequences, and consequences of lack of brain training have turned neurodegenerative diseases into common diseases. For those who have relatives with neurodegenerative diseases such as Alzheimer’s disease, there are invisible, slow and irreversible effects that completely destroy quality of life. The sublingual route of administration addresses many drug and patient needs and is useful for the elderly and psychiatric uncooperative patients with dysphagia (dysphagia). Highlights convenient dosing: sublingual administration has several advantages over oral formulations, including rapid absorption, predictable efficacy, reduced interactions with other medications and foods, and ease of administration The sublingual tablets have been delivered to the site and a Phase II trial will be initiated upon arrival.

    “Our main objectives in developing this formulation were based on providing a pain-free and scalable formulation that is inexpensive, convenient for repeated and long-term use. It is degraded by monoamine oxidase enzymes present in the gastrointestinal tract, preventing absorption into the circulatory and central nervous system, rendering it neurochemically inactive after oral administration. The addition of a monoamine oxidase inhibitor to protect the -MeO-DMT will be critical, as this factor significantly increases formulation complexity to maximize outcomes.”

    About Biomind Lab Co., Ltd.

    Biomind Labs is a biotechnology research and development company dedicated to translating knowledge in biomedical science into new pharmaceuticals and innovative nanotechnology delivery systems for a variety of psychiatric and neurological conditions. Biomind Labs has developed a key psychedelic molecule, N,N-dimethyltryptamine (“DMT”), 5-MeO-DMT and mescaline treat a wide range of therapeutic indications. Biomind Labs’ focus is on providing patients with affordable, modern therapies.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains statements that constitute “forward-looking information” (“forward-looking information”) within the meaning of applicable Canadian securities laws. All statements other than statements of historical fact are forward-looking information and are based on expectations, estimates and projections as of the date of this news release. Any statement discussing predictions, expectations, beliefs, plans, predictions, objectives, assumptions, future events, or performance (phrases such as “expect,” “do not expect,” “expect,” “predict,” etc.) is not always used) or “not expected”, “planned”, “budgeted”, “intended”, “forecast”, “estimate”, “believe”, “intend”, or such “could” or “could”, “could”, “could”, or “could” refer to variations of a word or phrase or a particular action, event or outcome “to be” is considered to occur or be achieved) may be forward-looking information rather than statements of historical fact. Forward-looking statements in this document include, among other things, statements regarding our ability to scientifically harness the efficacy of psychedelic molecules to treat patients suffering from neurological and psychiatric disorders; Contains our description of the exam. Candidate BMND08; company statement on its focus on potential solutions to these devastating diseases and potential improvements in neuroplasticity. Our ability to provide patients with access to affordable and modern treatments. and other statements that are not historical facts.

    By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, or other Future events may differ materially from any future results, performance or achievements expressed or implied by us. such forward-looking statements. Such factors and risks include, among others: (b) Comply with Extensive Government Regulations. (c) domestic and foreign laws and regulations may adversely affect our business and results of operations; (d) Stock markets experience volatility that is often unrelated to company performance, and these fluctuations may adversely affect the price of our securities, regardless of their peers. (e) A negative change in public perception of tryptamine-based and psychedelic-based therapies. (f) Impact of COVID-19. (g) general business, economic, competitive, political and social uncertainties; Readers should therefore not place undue reliance on the forward-looking information contained in this press release.

    We make no claims of medical, therapeutic, or health benefits for the products we suggest. The U.S. Food and Drug Administration, Health Canada, or other similar regulatory agencies have not evaluated claims regarding tryptamine-based treatments, psychedelic-based treatments, or other psychedelic compounds. There is no guarantee that the use of psychedelic tryptamine, tryptamine derivatives, or other psychedelic compounds will diagnose, treat, cure, or prevent any disease or condition. Substantial scientific research and clinical trials are needed. We have not yet completed any commercial clinical trials for the use of the proposed product. References to the quality, consistency, efficacy and safety of a potential product do not imply that we have so validated in commercial clinical trials or that we have completed such trials. If we are unable to obtain the necessary approvals and research for commercialization, our performance and operations could be materially and adversely affected.

    The forward-looking information contained in this news release represents our expectations as of the date of this news release and is therefore subject to change after that date. Readers should not place undue weight on forward-looking information or rely on this information as of any other date. We undertake no obligation to update these forward-looking statements if management’s beliefs, estimates, opinions or other factors change.

    Neo Exchange Inc. has not endorsed or disapproved of the content of this news release and is not responsible for the adequacy or accuracy of any content contained herein.



    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleStem cell therapy may slow multiple sclerosis better than drugs: study
    Next Article A rare case of two paraneoplastic neurological syndromes in a patient with lung cancer.
    brainwealthy_vws1ex
    • Website

    Related Posts

    FSU psychologist receives $3.7 million grant to combat anxiety in seniors with Alzheimer’s and cognitive impairment

    February 2, 2023

    How anxiety came to dominate the big business of medical marijuana cards in Pa.

    February 2, 2023

    How to Reduce Anxiety in Stressful Situations

    February 2, 2023
    Add A Comment

    Leave A Reply Cancel Reply

    Top Posts

    Subscribe to Updates

    Get the latest sports news from SportsSite about soccer, football and tennis.

    This website provides information about Brain and other things. Keep Supporting Us With the Latest News and we Will Provide the Best Of Our To Makes You Updated All Around The World News. Keep Sporting US.

    Facebook Twitter Instagram Pinterest YouTube
    Top Insights

    Top UK Stocks to Watch: Capita Shares Rise as it Unveils

    January 15, 2021
    8.5

    Digital Euro Might Suck Away 8% of Banks’ Deposits

    January 12, 2021

    Oil Gains on OPEC Outlook That U.S. Growth Will Slow

    January 11, 2021
    Get Informed

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    © 2023 brainwealthy. Designed by brainwealthy.
    • Home
    • Contact us
    • DMCA
    • Privacy Policy

    Type above and press Enter to search. Press Esc to cancel.